Print

NeoStem, Inc. Letter to Shareholders  
9/25/2013 9:14:40 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, Sept. 25, 2013 (GLOBE NEWSWIRE) --

Dear NeoStem Shareholders,

NeoStem (Nasdaq:NBS), a leader in the emerging cellular therapy market, continues to position itself for success through scientific discovery, a diversified product development pipeline that addresses cardiovascular and autoimmune diseases as well as regenerative medicine, an expanding contract development and manufacturing business that serves as its revenue generating arm, and a professional and experienced management team.

Help employers find you! Check out all the jobs and post your resume.

//-->